Table of Content

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Immunoglobulin Replacement Therapy
1.2.3 Stem Cell or Bone Marrow Transplantation
1.2.4 Antibiotic Therapy
1.2.5 Gene Therapy
1.2.6 Others
1.3 Market by Application
1.3.1 Global Primary Immunodeficiency Therapeutic Market Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Antibody Deficiency
1.3.3 Cellular Immunodeficiency
1.3.4 Innate Immune Disorders
1.3.5 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Primary Immunodeficiency Therapeutic Market Perspective (2018-2029)
2.2 Primary Immunodeficiency Therapeutic Growth Trends by Region
2.2.1 Global Primary Immunodeficiency Therapeutic Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Primary Immunodeficiency Therapeutic Historic Market Size by Region (2018-2024)
2.2.3 Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2024-2029)
2.3 Primary Immunodeficiency Therapeutic Market Dynamics
2.3.1 Primary Immunodeficiency Therapeutic Industry Trends
2.3.2 Primary Immunodeficiency Therapeutic Market Drivers
2.3.3 Primary Immunodeficiency Therapeutic Market Challenges
2.3.4 Primary Immunodeficiency Therapeutic Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Primary Immunodeficiency Therapeutic Players by Revenue
3.1.1 Global Top Primary Immunodeficiency Therapeutic Players by Revenue (2018-2024)
3.1.2 Global Primary Immunodeficiency Therapeutic Revenue Market Share by Players (2018-2024)
3.2 Global Primary Immunodeficiency Therapeutic Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Primary Immunodeficiency Therapeutic Revenue
3.4 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio
3.4.1 Global Primary Immunodeficiency Therapeutic Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Primary Immunodeficiency Therapeutic Revenue in 2022
3.5 Primary Immunodeficiency Therapeutic Key Players Head office and Area Served
3.6 Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
3.7 Date of Enter into Primary Immunodeficiency Therapeutic Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Primary Immunodeficiency Therapeutic Breakdown Data by Type
4.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Type (2018-2024)
4.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2024-2029)
5 Primary Immunodeficiency Therapeutic Breakdown Data by Application
5.1 Global Primary Immunodeficiency Therapeutic Historic Market Size by Application (2018-2024)
5.2 Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Primary Immunodeficiency Therapeutic Market Size (2018-2029)
6.2 North America Primary Immunodeficiency Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
6.4 North America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Primary Immunodeficiency Therapeutic Market Size (2018-2029)
7.2 Europe Primary Immunodeficiency Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
7.4 Europe Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size (2018-2029)
8.2 Asia-Pacific Primary Immunodeficiency Therapeutic Market Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024)
8.4 Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Primary Immunodeficiency Therapeutic Market Size (2018-2029)
9.2 Latin America Primary Immunodeficiency Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
9.4 Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size (2018-2029)
10.2 Middle East & Africa Primary Immunodeficiency Therapeutic Market Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024)
10.4 Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Baxter International
11.1.1 Baxter International Company Detail
11.1.2 Baxter International Business Overview
11.1.3 Baxter International Primary Immunodeficiency Therapeutic Introduction
11.1.4 Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.1.5 Baxter International Recent Development
11.2 Takeda Pharmaceutical
11.2.1 Takeda Pharmaceutical Company Detail
11.2.2 Takeda Pharmaceutical Business Overview
11.2.3 Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Introduction
11.2.4 Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.2.5 Takeda Pharmaceutical Recent Development
11.3 CSL Limited
11.3.1 CSL Limited Company Detail
11.3.2 CSL Limited Business Overview
11.3.3 CSL Limited Primary Immunodeficiency Therapeutic Introduction
11.3.4 CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.3.5 CSL Limited Recent Development
11.4 Octapharma
11.4.1 Octapharma Company Detail
11.4.2 Octapharma Business Overview
11.4.3 Octapharma Primary Immunodeficiency Therapeutic Introduction
11.4.4 Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.4.5 Octapharma Recent Development
11.5 Kedrion Biopharma
11.5.1 Kedrion Biopharma Company Detail
11.5.2 Kedrion Biopharma Business Overview
11.5.3 Kedrion Biopharma Primary Immunodeficiency Therapeutic Introduction
11.5.4 Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.5.5 Kedrion Biopharma Recent Development
11.6 Bio Products Laboratory
11.6.1 Bio Products Laboratory Company Detail
11.6.2 Bio Products Laboratory Business Overview
11.6.3 Bio Products Laboratory Primary Immunodeficiency Therapeutic Introduction
11.6.4 Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.6.5 Bio Products Laboratory Recent Development
11.7 LFB group
11.7.1 LFB group Company Detail
11.7.2 LFB group Business Overview
11.7.3 LFB group Primary Immunodeficiency Therapeutic Introduction
11.7.4 LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.7.5 LFB group Recent Development
11.8 Grifols
11.8.1 Grifols Company Detail
11.8.2 Grifols Business Overview
11.8.3 Grifols Primary Immunodeficiency Therapeutic Introduction
11.8.4 Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.8.5 Grifols Recent Development
11.9 Lupin Pharmaceuticals
11.9.1 Lupin Pharmaceuticals Company Detail
11.9.2 Lupin Pharmaceuticals Business Overview
11.9.3 Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Introduction
11.9.4 Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024)
11.9.5 Lupin Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Figure

List of Tables
Table 1. Global Primary Immunodeficiency Therapeutic Market Size Growth Rate by Type (US$ Million): 2018 VS 2022 VS 2029
Table 2. Key Players of Immunoglobulin Replacement Therapy
Table 3. Key Players of Stem Cell or Bone Marrow Transplantation
Table 4. Key Players of Antibiotic Therapy
Table 5. Key Players of Gene Therapy
Table 6. Key Players of Others
Table 7. Global Primary Immunodeficiency Therapeutic Market Size Growth by Application (US$ Million): 2018 VS 2022 VS 2029
Table 8. Global Primary Immunodeficiency Therapeutic Market Size by Region (US$ Million): 2018 VS 2022 VS 2029
Table 9. Global Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 10. Global Primary Immunodeficiency Therapeutic Market Share by Region (2018-2024)
Table 11. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Region (2024-2029) & (US$ Million)
Table 12. Global Primary Immunodeficiency Therapeutic Market Share by Region (2024-2029)
Table 13. Primary Immunodeficiency Therapeutic Market Trends
Table 14. Primary Immunodeficiency Therapeutic Market Drivers
Table 15. Primary Immunodeficiency Therapeutic Market Challenges
Table 16. Primary Immunodeficiency Therapeutic Market Restraints
Table 17. Global Primary Immunodeficiency Therapeutic Revenue by Players (2018-2024) & (US$ Million)
Table 18. Global Primary Immunodeficiency Therapeutic Market Share by Players (2018-2024)
Table 19. Global Top Primary Immunodeficiency Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2022)
Table 20. Ranking of Global Top Primary Immunodeficiency Therapeutic Companies by Revenue (US$ Million) in 2022
Table 21. Global 5 Largest Players Market Share by Primary Immunodeficiency Therapeutic Revenue (CR5 and HHI) & (2018-2024)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Primary Immunodeficiency Therapeutic Product Solution and Service
Table 24. Date of Enter into Primary Immunodeficiency Therapeutic Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Primary Immunodeficiency Therapeutic Market Size by Type (2018-2024) & (US$ Million)
Table 27. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2018-2024)
Table 28. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Type (2024-2029) & (US$ Million)
Table 29. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Type (2024-2029)
Table 30. Global Primary Immunodeficiency Therapeutic Market Size by Application (2018-2024) & (US$ Million)
Table 31. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2018-2024)
Table 32. Global Primary Immunodeficiency Therapeutic Forecasted Market Size by Application (2024-2029) & (US$ Million)
Table 33. Global Primary Immunodeficiency Therapeutic Revenue Market Share by Application (2024-2029)
Table 34. North America Primary Immunodeficiency Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 35. North America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 36. North America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 37. Europe Primary Immunodeficiency Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 38. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 39. Europe Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 40. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size Growth Rate by Region (US$ Million): 2018 VS 2022 VS 2029
Table 41. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2018-2024) & (US$ Million)
Table 42. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size by Region (2024-2029) & (US$ Million)
Table 43. Latin America Primary Immunodeficiency Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 44. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 45. Latin America Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 46. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size Growth Rate by Country (US$ Million): 2018 VS 2022 VS 2029
Table 47. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2018-2024) & (US$ Million)
Table 48. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size by Country (2024-2029) & (US$ Million)
Table 49. Baxter International Company Detail
Table 50. Baxter International Business Overview
Table 51. Baxter International Primary Immunodeficiency Therapeutic Product
Table 52. Baxter International Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 53. Baxter International Recent Development
Table 54. Takeda Pharmaceutical Company Detail
Table 55. Takeda Pharmaceutical Business Overview
Table 56. Takeda Pharmaceutical Primary Immunodeficiency Therapeutic Product
Table 57. Takeda Pharmaceutical Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 58. Takeda Pharmaceutical Recent Development
Table 59. CSL Limited Company Detail
Table 60. CSL Limited Business Overview
Table 61. CSL Limited Primary Immunodeficiency Therapeutic Product
Table 62. CSL Limited Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 63. CSL Limited Recent Development
Table 64. Octapharma Company Detail
Table 65. Octapharma Business Overview
Table 66. Octapharma Primary Immunodeficiency Therapeutic Product
Table 67. Octapharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 68. Octapharma Recent Development
Table 69. Kedrion Biopharma Company Detail
Table 70. Kedrion Biopharma Business Overview
Table 71. Kedrion Biopharma Primary Immunodeficiency Therapeutic Product
Table 72. Kedrion Biopharma Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 73. Kedrion Biopharma Recent Development
Table 74. Bio Products Laboratory Company Detail
Table 75. Bio Products Laboratory Business Overview
Table 76. Bio Products Laboratory Primary Immunodeficiency Therapeutic Product
Table 77. Bio Products Laboratory Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 78. Bio Products Laboratory Recent Development
Table 79. LFB group Company Detail
Table 80. LFB group Business Overview
Table 81. LFB group Primary Immunodeficiency Therapeutic Product
Table 82. LFB group Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 83. LFB group Recent Development
Table 84. Grifols Company Detail
Table 85. Grifols Business Overview
Table 86. Grifols Primary Immunodeficiency Therapeutic Product
Table 87. Grifols Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 88. Grifols Recent Development
Table 89. Lupin Pharmaceuticals Company Detail
Table 90. Lupin Pharmaceuticals Business Overview
Table 91. Lupin Pharmaceuticals Primary Immunodeficiency Therapeutic Product
Table 92. Lupin Pharmaceuticals Revenue in Primary Immunodeficiency Therapeutic Business (2018-2024) & (US$ Million)
Table 93. Lupin Pharmaceuticals Recent Development
Table 94. Research Programs/Design for This Report
Table 95. Key Data Information from Secondary Sources
Table 96. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Primary Immunodeficiency Therapeutic Market Size Comparison by Type (2024-2029) & (US$ Million)
Figure 2. Global Primary Immunodeficiency Therapeutic Market Share by Type: 2022 VS 2029
Figure 3. Immunoglobulin Replacement Therapy Features
Figure 4. Stem Cell or Bone Marrow Transplantation Features
Figure 5. Antibiotic Therapy Features
Figure 6. Gene Therapy Features
Figure 7. Others Features
Figure 8. Global Primary Immunodeficiency Therapeutic Market Size Comparison by Application (2024-2029) & (US$ Million)
Figure 9. Global Primary Immunodeficiency Therapeutic Market Share by Application: 2022 VS 2029
Figure 10. Antibody Deficiency Case Studies
Figure 11. Cellular Immunodeficiency Case Studies
Figure 12. Innate Immune Disorders Case Studies
Figure 13. Others Case Studies
Figure 14. Primary Immunodeficiency Therapeutic Report Years Considered
Figure 15. Global Primary Immunodeficiency Therapeutic Market Size (US$ Million), Year-over-Year: 2018-2029
Figure 16. Global Primary Immunodeficiency Therapeutic Market Size, (US$ Million), 2018 VS 2022 VS 2029
Figure 17. Global Primary Immunodeficiency Therapeutic Market Share by Region: 2022 VS 2029
Figure 18. Global Primary Immunodeficiency Therapeutic Market Share by Players in 2022
Figure 19. Global Top Primary Immunodeficiency Therapeutic Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Primary Immunodeficiency Therapeutic as of 2022)
Figure 20. The Top 10 and 5 Players Market Share by Primary Immunodeficiency Therapeutic Revenue in 2022
Figure 21. North America Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 22. North America Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 23. United States Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 24. Canada Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 25. Europe Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 26. Europe Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 27. Germany Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 28. France Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 29. U.K. Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 30. Italy Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 31. Russia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 32. Nordic Countries Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 33. Asia-Pacific Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 34. Asia-Pacific Primary Immunodeficiency Therapeutic Market Share by Region (2018-2029)
Figure 35. China Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 36. Japan Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 37. South Korea Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 38. Southeast Asia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 39. India Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 40. Australia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 41. Latin America Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 42. Latin America Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 43. Mexico Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 44. Brazil Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 45. Middle East & Africa Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 46. Middle East & Africa Primary Immunodeficiency Therapeutic Market Share by Country (2018-2029)
Figure 47. Turkey Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 48. Saudi Arabia Primary Immunodeficiency Therapeutic Market Size YoY Growth (2018-2029) & (US$ Million)
Figure 49. Baxter International Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 50. Takeda Pharmaceutical Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 51. CSL Limited Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 52. Octapharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 53. Kedrion Biopharma Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 54. Bio Products Laboratory Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 55. LFB group Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 56. Grifols Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 57. Lupin Pharmaceuticals Revenue Growth Rate in Primary Immunodeficiency Therapeutic Business (2018-2024)
Figure 58. Bottom-up and Top-down Approaches for This Report
Figure 59. Data Triangulation
Figure 60. Key Executives Interviewed